Wos Açık Erişimli Yayınlar

Permanent URI for this collectionhttps://hdl.handle.net/11727/10754

Browse

Filters

20183

Settings

search.filters.applied.f.rights: search.filters.rights.info:eu-repo/semantics/openAccessSubject: search.filters.subject.Cardiovascular disease

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Importance of laboratory parameters in patients with obstructive sleep apnea and their relationship with cardiovascular diseases
    (2018) Kulaksizoglu, Sevsen; Kivanc, Tulay; Lakadamyali, Huseyin; Eyuboglu, Fusun; 0000-0002-7613-2240; 0000-0002-5525-8207; 28345811; AAI-8932-2021; AAR-4338-2020
    BackgroundOstructive sleep apnea (OSA) is an independent risk factor for the development of cardiovascular events. Platelet activation and inflammation are the mechanisms involved in the association between OSA and cardiovascular disease (CVD). The markers of platelet activation and inflammation are the mean platelet volume (MPV), platelet-lymphocyte ratio (PLR), red cell distribution width (RDW), neutrophil- lymphocyte ratio (NLR). We aimed to define the association of NLR, PLR, RDW, and MPV with the severity of disease and the presence of CVD. MethodsThis study consisted of 300 patients who were admitted to the sleep laboratory. The patients were classified according to their apnea- hypopnea index (AHI) scores as OSA negative (Group A: AHI<5), mild (Group B: AHI: 5-15), moderate (Group C: AHI=15-30), and severe OSA (Group D: AHI >30). ResultsThere were no significant differences in the NLR, PLR, and MPV among the groups (P>.05); only RDW differed significantly (P=.04). RDW was significantly higher in patients with than without risk factors for CVD [15.6% (15.4-15.7) vs 15.3% (15.1-15.3), respectively; P=.02]. ConclusionsNLR, PLR, MPV, and RDW are widely available and easily obtained from a routinely performed hemogram. Among these laboratory parameters, only RDW can demonstrate the reverse consequences of OSA-associated comorbidities, because vascular damage due to systemic inflammation is an important underlying mechanism in these diseases. RDW might be used as a marker of the response and patient compliance with continuous positive airway pressure treatment.
  • Thumbnail Image
    Item
    The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox
    (2018) Ozkalayci, Flora; Gulmez, Oyku; Ugur-Altun, Betul; Pandi-Pemural, Seithikurippu Ratnas; Altun A, Armagan
    Cardiovascular disease is one of the most frequent causes of mortality and morbidity worldwide. Several variables have been identified as risk factors for cardiovascular disease. Recently, the role of receptor activator of nuclear factor kappa B, receptor activator of nuclear factor kappa B ligand, and the osteoprotegerin system has been recognized as more important in the pathogenesis of cardiovascular disease. Besides their roles in the regulation of bone resorption, these molecules have been reported to be associated with the pathophysiology of cardiovascular disease. There are conflicting data regarding the impact of osteoprotegerin, a glycoprotein with a regulatory role in the cardiovascular system. The aim of this review is to discuss the current knowledge and the role of osteoprotegerin in cardiovascular disease.
  • Thumbnail Image
    Item
    Approach to cardiovascular disease in women
    (2018) Gulmez, Oyku; Acar, Rezzan Deniz; Aktoz, Meryem; Atamer, Oya; Aytekin, Saide; Polat, Evin Bozcali; Celik, Hulya Gamze; Celik, Omer; Elcioglu, Betul Cengiz; Dincer, İrem; Gazi, Emine; Kayikcioglu, Meral; Keser, Nurgul; Ozer, Necla; Yasar, Ayse Saatci; Sahinarslan, Asife; Kurklu, Turkan Seda Tan; Tokgozoglu, Lale; Yamac, Aylin Hatice; Yildirimturk, Ozlem; Yilmaz, Dilek Cicek; Yilmaz, Neslihan
    Cardiovascular disease (CVD) in women is still not completely understood by either patients or physicians. It is perceived as a health problem that becomes manifest only after menopause; however, it is the most frequent cause of mortality in women and is often seen at an earlier age in the presence of risk factors. Moreover, the symptoms, course, and prognosis are quite different from those seen in men, and both physicians and patients remain inadequately aware of the character of the disease. In the approach to female patients, some risk factors inherent to women should be considered in addition to the classic factors. In this review article, aspects of CVD that are different in women, etiological factors, risk factors specific to women, and particular points to be taken into consideration in the treatment and diagnosis are illustrated in the form of questions and responses from experts.